ERNA (Ernexa Therapeutics) Common Stock: $0.01 Mil (As of Mar. 2026)


ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $5.76
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Common Stock?

Ernexa Therapeutics ERNA -7.58% 30 Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Ernexa Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.04 Mil) to Dec. 2025 ($0.04 Mil) but then declined from Dec. 2025 ($0.04 Mil) to Mar. 2026 ($0.01 Mil).

Ernexa Therapeutics's annual common stock declined from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.02 Mil) but then increased from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.04 Mil).

Ernexa Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Ernexa Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics Common Stock Chart

Ernexa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial 0.01 0.03 0.03 0.02 0.04

Ernexa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.04 0.04 0.04 0.01
ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Ernexa Therapeutics (ERNA) has a Common Stock of $0.01 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Ernexa Therapeutics and its competitors.
Is Ernexa Therapeutics' Common Stock too high?
Ernexa Therapeutics' current Common Stock is $0.01 Mil. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Common Stock compare to PMCB and SYBX?
Ernexa Therapeutics' Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Common Stock is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.76
Price